What are the clinical features, diagnostic work‑up, and treatment recommendations for Alport syndrome?

Alport Syndrome: Clinical Features, Diagnosis, and Management

Clinical Features

Alport syndrome is a hereditary glomerular basement membrane disease characterized by the triad of progressive kidney disease (hematuria → proteinuria → renal failure), sensorineural hearing loss, and ocular abnormalities. 1, 2

Renal Manifestations

• Persistent microscopic hematuria is the earliest and most consistent finding, present from birth or early childhood 2, 3
• Episodic gross hematuria may occur, often triggered by upper respiratory infections 2
• Proteinuria develops progressively, typically appearing in late childhood to adolescence 4, 5
• Progressive decline in renal function leads to end-stage renal disease (ESRD), with timing dependent on inheritance pattern and specific mutations 3, 5
• Males with X-linked disease typically reach ESRD by age 20-30 years 6

Auditory Manifestations

• High-frequency (bilateral) sensorineural hearing loss develops due to cochlear basement membrane abnormalities 1, 2
• Hearing loss is progressive and typically manifests in late childhood or adolescence, often coinciding with worsening proteinuria 5, 6
• Present in approximately 85% of affected males with X-linked disease by adulthood 6

Ocular Manifestations

• Anterior lenticonus (conical protrusion of the lens) occurs in approximately 25% of affected males and is highly specific for Alport syndrome 6
• Dot-and-fleck retinopathy appears in about 85% of affected adult males and is diagnostic when present with family history or renal disease 6
• Posterior polymorphous corneal dystrophy is rare but highly suggestive of Alport syndrome 6
• Other findings include cataracts, spontaneous lens rupture, and various corneal abnormalities 6

Genetic Patterns and Phenotype Correlations

• X-linked inheritance (COL4A5 mutations) accounts for approximately 85% of cases 4, 3
• Autosomal recessive (COL4A3/COL4A4 mutations) presents with clinical features identical to X-linked disease 6
• Autosomal dominant is now recognized as the most common form, though typically with milder phenotype 7
• Digenic inheritance (concurrent mutations in multiple COL4A genes) can result in more severe or earlier-onset disease 8, 4

Diagnostic Work-Up

Genetic testing with a COL4A3/COL4A4/COL4A5 gene panel is the preferred diagnostic approach and should be performed in all suspected cases. 1, 3

Initial Clinical Assessment

• Detailed family history focusing on renal failure, hearing loss, and early dialysis or transplantation in relatives 2
• Growth charts to assess failure to thrive or delayed development 1
• Blood pressure measurement (often normal or low initially) 2

Laboratory Evaluation

• Urinalysis demonstrating persistent microscopic hematuria 3, 5
• Urine protein-to-creatinine ratio to quantify proteinuria 1
• Serum creatinine and eGFR to assess renal function 1
• Baseline measurements should be obtained every 3-6 months during stable disease 1

Imaging Studies

• Renal ultrasound at diagnosis to evaluate kidney size and parenchymal echogenicity, providing baseline for progression monitoring 1, 8
• Kidneys may appear normal-sized early or become small with advanced disease 8
• Cystic changes are not typical 8

Specialized Testing

• Baseline high-frequency audiometry to detect early sensorineural hearing loss 1
• Repeat audiometry every 1-2 years to monitor progression 1
• Comprehensive ophthalmologic examination including slit-lamp evaluation for anterior lenticonus and fundoscopy for dot-and-fleck retinopathy 6

Genetic Testing Strategy

• Gene panel testing for COL4A3, COL4A4, and COL4A5 is recommended for all clinically suspected cases 1, 3
• Genetic diagnosis confirms the specific inheritance pattern, guides prognosis, and enables family screening 4, 3
• Approximately 10% of X-linked cases arise from de novo COL4A5 mutations, so absence of family history does not exclude diagnosis 1

Renal Biopsy Considerations

• Electron microscopy remains the gold standard when genetic testing is unavailable or inconclusive, showing characteristic thinning, splitting, and lamellation of the glomerular basement membrane 2, 8
• The 2021 KDIGO guidelines suggest treatment may proceed without biopsy when Alport syndrome is strongly suspected based on family history, pathogenic mutations, and characteristic extrarenal manifestations 8

Critical Diagnostic Distinction

• Distinguish from Goodpasture syndrome, which presents acutely over days-to-weeks with rapidly progressive glomerulonephritis and pulmonary hemorrhage in previously healthy adults, versus Alport's insidious onset from childhood with years-long progression 2
• Differentiate from thin basement membrane disease and IgA nephropathy by positive family history of renal failure, hearing loss, and progressive course 2

Treatment Recommendations

Initiate renin-angiotensin-aldosterone system (RAAS) blockade early to delay progression to ESRD, targeting blood pressure ≤125/80 mmHg. 1, 5

Renoprotective Therapy

• ACE inhibitors or ARBs are proven to delay onset of renal failure by reducing proteinuria 5, 7
• Target blood pressure of ≤125/80 mmHg to maximize renal protection 1
• Early initiation, even before significant proteinuria develops, may provide maximal benefit 7

Monitoring Intensification

• Measure serum creatinine, eGFR, and proteinuria every 3-6 months during stable disease 1
• Intensify monitoring to every 2-4 weeks when proteinuria increases or eGFR declines to allow timely therapeutic adjustment 1

Management of Extrarenal Manifestations

• Hearing aids for progressive sensorineural hearing loss (only supportive measures available) 4, 5
• Ophthalmologic management of anterior lenticonus and other ocular complications 5
• No specific curative treatments exist for hearing or visual loss 5

Advanced Renal Disease Management

• Hemodialysis or peritoneal dialysis for end-stage renal disease 4
• Renal transplantation is curative for kidney failure and offers excellent outcomes 5
• Critical caveat: Alport patients may develop anti-GBM disease after kidney transplantation, requiring maintenance immunosuppression similar to ANCA-associated vasculitis if double-positive for ANCA and anti-GBM antibodies 2

Anticoagulation in Proteinuric States

• Avoid factor Xa inhibitors and direct thrombin inhibitors due to unpredictable pharmacokinetics in nephrotic-range proteinuria 1
• Prefer warfarin when anticoagulation is required 1

Family Screening and Genetic Counseling

All first-degree relatives of an affected individual must be evaluated due to the hereditary nature of Alport syndrome. 1

X-Linked Inheritance Counseling (Male Proband)

• Sons of affected males: 0% risk (no male-to-male transmission) 1
• Daughters of affected males: 100% carrier risk (obligate carriers) 1
• Brothers of affected males: 50% risk of being affected 1
• Mother and sisters: Should undergo carrier testing 1

Carrier Manifestations

• Female carriers may develop microhematuria, proteinuria, and progressive renal disease, though typically milder and later-onset than affected males 1

Family Screening Protocol

• Targeted genetic testing for the known pathogenic variant in all at-risk family members 1
• Phenotypic screening of both female carriers and hemizygous males using urinalysis, urine protein-to-creatinine ratio, serum creatinine, audiometry, and ophthalmologic examination 1
• Genetic counseling on reproductive options, including pre-implantation genetic diagnosis and prenatal testing, tailored to local ethical and legal frameworks 1